BioNTech SE (BNTX)

BioNTech SE Statistics

Total Valuation

BioNTech SE has a market cap or net worth of $23.38 billion. The enterprise value is $8.45 billion.

Market Cap	23.38B
Enterprise Value	8.45B

Important Dates

The last earnings date was Monday, May 5, 2025, before market open.

Earnings Date	May 5, 2025
Ex-Dividend Date	n/a

Share Statistics

BioNTech SE has 240.39 million shares outstanding. The number of shares has decreased by -0.51% in one year.

Current Share Class	n/a
Shares Outstanding	240.39M
Shares Change (YoY)	-0.51%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	18.77%
Owned by Institutions (%)	22.51%
Float	92.78M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.88
Forward PS	9.53
PB Ratio	1.14
P/TBV Ratio	1.27
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	2.85
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 10.18, with a Debt / Equity ratio of 0.02.

Current Ratio	10.18
Quick Ratio	9.86
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-80.81

Financial Efficiency

Return on equity (ROE) is -3.94% and return on invested capital (ROIC) is -4.05%.

Return on Equity (ROE)	-3.94%
Return on Assets (ROA)	-3.67%
Return on Invested Capital (ROIC)	-4.05%
Return on Capital Employed (ROCE)	-6.50%
Revenue Per Employee	$438,324
Profits Per Employee	-$122,258
Employee Count	6,772
Asset Turnover	0.13
Inventory Turnover	1.89

Taxes

Income Tax	-27.35M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +6.11% in the last 52 weeks. The beta is 1.36, so BioNTech SE's price volatility has been higher than the market average.

Beta (5Y)	1.36
52-Week Price Change	+6.11%
50-Day Moving Average	99.57
200-Day Moving Average	106.74
Relative Strength Index (RSI)	47.29
Average Volume (20 Days)	1,460,000

Short Selling Information

Short Interest	4.63M
Short Previous Month	4.34M
Short % of Shares Out	5.02%
Short % of Float	n/a
Short Ratio (days to cover)	3.00

Income Statement

In the last 12 months, BioNTech SE had revenue of $2.97 billion and -$827.93 million in losses. Loss per share was -$3.45.

Revenue	2.97B
Gross Profit	2.36B
Operating Income	-1.38B
Pretax Income	-269.98M
Net Income	-827.93M
EBITDA	-1.10B
EBIT	-1.38B
Loss Per Share	-$3.45

Balance Sheet

The company has $15.25 billion in cash and $316.69 million in debt, giving a net cash position of $14.93 billion or $62.12 per share.

Cash & Cash Equivalents	15.25B
Total Debt	316.69M
Net Cash	14.93B
Net Cash Per Share	$62.12
Equity (Book Value)	20.46B
Book Value Per Share	85.10
Working Capital	15.23B

Cash Flow

In the last 12 months, operating cash flow was -$276.37 million and capital expenditures -$299.29 million, giving a free cash flow of -$590.92 million.

Operating Cash Flow	-276.37M
Capital Expenditures	-299.29M
Free Cash Flow	-590.92M
FCF Per Share	-$2.46

Margins

Gross margin is 79.39%, with operating and profit margins of -46.49% and -27.89%.

Gross Margin	79.39%
Operating Margin	-46.49%
Pretax Margin	-28.81%
Profit Margin	-27.89%
EBITDA Margin	-37.14%
EBIT Margin	-46.49%
FCF Margin	n/a

Dividends & Yields

BioNTech SE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.51%
Shareholder Yield	0.51%
Earnings Yield	-3.54%
FCF Yield	-2.53%

Analyst Forecast

The average price target for BioNTech SE is $145.17, which is 49.24% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$145.17
Price Target Difference	49.24%
Analyst Consensus	Strong Buy
Analyst Count	17
Revenue Growth Forecast (5Y)	4.83%
EPS Growth Forecast (5Y)	-19.52%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioNTech SE has an Altman Z-Score of 8.04 and a Piotroski F-Score of 3.

Altman Z-Score	8.04
Piotroski F-Score	3